Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. for allegedly making misleading statements regarding its financial performance and growth prospects [1][2]. Group 1: Lawsuit Details - The lawsuit, titled Alonzo v. DexCom, Inc., represents investors who purchased DexCom securities between January 8, 2024, and July 25, 2024 [2]. - Plaintiffs claim that DexCom and its executives violated federal securities laws by providing false and misleading information about the company's growth, earnings potential, and margins [2]. - The lawsuit alleges that DexCom overstated its ability to attract new customers and maintain existing distribution channels [2]. Group 2: Financial Performance - On July 25, 2024, DexCom announced disappointing financial results for Q2 2024 and lowered its revenue guidance for the full year, attributing the shortfall to unmet expectations from several key strategic initiatives [2]. - Following the announcement, DexCom's stock price fell by nearly 41% [3]. Group 3: Investigation and Whistleblower Information - Hagens Berman, a prominent shareholder rights firm, has initiated an investigation into potential violations of U.S. securities laws by DexCom [3]. - The investigation aims to determine whether DexCom misled the public about the risks associated with its strategic decisions [3]. - Whistleblowers with non-public information regarding DexCom are encouraged to assist in the investigation, with potential rewards under the SEC Whistleblower program [3].

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) an ...

Core Viewpoint - A securities class action lawsuit has been filed against DexCom, Inc. for allegedly making false and misleading statements regarding its business performance and growth prospects during the specified Class Period from January 8, 2024, to July 25, 2024 [1][2]. Group 1: Allegations Against DexCom - The complaint claims that DexCom's statements about growth and anticipated margins were overly optimistic, primarily due to reliance on attracting new customers [2]. - It is alleged that DexCom faced challenges in maintaining successful existing distribution channels [2]. - As a result, the statements made by DexCom regarding its business operations and future prospects were materially false and misleading [2]. Group 2: Lead Plaintiff Process - Investors in DexCom have until October 21, 2024, to seek appointment as a lead plaintiff representative for the class through Kessler Topaz Meltzer & Check, LLP or other counsel [3]. - A lead plaintiff acts on behalf of all class members and typically is the investor or small group with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [3]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [5]. - The firm encourages DexCom investors who have experienced significant losses to contact them for more information [4].

NEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of those who acquired Dexcom Inc. (“Dexcom” or the “Company”) (NASDAQ: DXCM) securities during the period of January 8, 2024 to July 25, 2024, inclusive (“the Class Period”). Investors have until October 21, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. [Click h ...

SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired DexCom Inc. (NASDAQ: DXCM) securities between January 8, 2024 and July 25, 2024. DexCom is an international company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In DexCom To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in DexCom between January 8, 2024 to July 25, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 25, 2024 (GLOBE NEW ...

Two key uncertainties make the prospect of buying it today riskier than is desirable.DexCom (DXCM -0.95%) is not a stock that investors should be rushing to sell. It has a few different opportunities to continue pursuing to generate growth, it has plenty of recurring revenue, and the valuation of its shares is reasonable. But you still shouldn't buy it right now.The odds are good that it'll continue to be a decent performer moving forward. Still, it's facing two key issues that need to be navigated successf ...

It isn't the most likely candidate to make someone a millionaire, but it's theoretically possible.With the company's market cap of $28 billion today, it's important to recognize that DexCom (DXCM -1.49%) is already one of the world's biggest medical device manufacturers. It therefore isn't likely to explode higher in value overnight, or even over the course of a couple of years.If it's going to be capable of making its investors into millionaires, those investors will need to commit a substantial amount of ...

Group 1 - A lawsuit has been filed against DexCom, Inc. and certain senior executives, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2] - DexCom develops glucose monitoring systems for diabetes management and aimed to capitalize on growth potential while scaling customer conversion to the new G7 platform [2] - Following disappointing earnings results for Q2 2024, DexCom reduced its full-year revenue guidance from $4.35 billion to a range of $4 billion to $4.05 billion, leading to a significant stock price decline of 38% [2] Group 2 - The stock price of DexCom closed at $107.85 per share on July 25, 2024, and dropped to $66.60 per share the following day, a decrease of $41.25 per share [2] - Bleichmar Fonti & Auld LLP is a leading international law firm specializing in securities class actions and has a strong track record, including recovering over $900 million from Tesla's Board of Directors [3][4]

NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM). Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form/?id=104521&from=3 CLASS PERIOD: January 8, 2024 to J ...